Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A D Tselepis

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
FEBS Letters|August 19, 1991
A PAF-acetylhydrolase activity in Tetrahymena pyriformis cellsA D Tselepis, M E Lekka, D Tsoukatos
International Journal of Cardiology|March 18, 2015
Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectivesI C Moschonas, J A Goudevenos, A D Tselepis
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|December 30, 2011
The metabolic role of retinol binding protein 4: an updateG A Christou, A D Tselepis, D N Kiortsis
Biochimica Et Biophysica Acta|November 3, 1993
Studies on the subcellular distribution of 1-O-alkyl-2-acetyl-sn-glycero phosphocholine (PAF) and on the enzymic activities involved in its biosynthesis within the ciliate Tetrahymena pyriformisD C Tsoukatos, A D Tselepis, M E Lekka
Biochimica Et Biophysica Acta|February 16, 1996
Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolaseC Dentan, A D Tselepis, M J Chapman, et al.
European Journal of Clinical Investigation|October 1, 1991
Platelet response to the aggregatory effect of platelet activating factor (PAF) ex vivo in patients with acute myocardial infarctionA D Tselepis, D Tsoukatos, C Droudes, et al.
European Journal of Endocrinology|May 7, 1999
Lipoprotein (a) levels, apolipoprotein (a) phenotypes and thyroid autoimmunityE T Bairaktari, A D Tselepis, H J Millionis, et al.
Zeitschrift Fur Naturforschung. C, Journal of Biosciences|September 1, 1988
Semisynthetic preparation of 1-O-hexadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet activating factor)M E Lekka, D C Tsoukatos, A D Tselepis, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 1, 1995
PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzymeA D Tselepis, C Dentan, S A Karabina, et al.
Journal of Biotechnology|February 7, 2006
Use of ionic liquids as media for the biocatalytic preparation of flavonoid derivatives with antioxidant potencyM H Katsoura, A C Polydera, L Tsironis, et al.
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
FEBS Letters|August 19, 1991
A PAF-acetylhydrolase activity in Tetrahymena pyriformis cellsA D Tselepis, M E Lekka, D Tsoukatos
International Journal of Cardiology|March 18, 2015
Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectivesI C Moschonas, J A Goudevenos, A D Tselepis
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|December 30, 2011
The metabolic role of retinol binding protein 4: an updateG A Christou, A D Tselepis, D N Kiortsis
Biochimica Et Biophysica Acta|November 3, 1993
Studies on the subcellular distribution of 1-O-alkyl-2-acetyl-sn-glycero phosphocholine (PAF) and on the enzymic activities involved in its biosynthesis within the ciliate Tetrahymena pyriformisD C Tsoukatos, A D Tselepis, M E Lekka
Biochimica Et Biophysica Acta|February 16, 1996
Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolaseC Dentan, A D Tselepis, M J Chapman, et al.
European Journal of Clinical Investigation|October 1, 1991
Platelet response to the aggregatory effect of platelet activating factor (PAF) ex vivo in patients with acute myocardial infarctionA D Tselepis, D Tsoukatos, C Droudes, et al.
European Journal of Endocrinology|May 7, 1999
Lipoprotein (a) levels, apolipoprotein (a) phenotypes and thyroid autoimmunityE T Bairaktari, A D Tselepis, H J Millionis, et al.
Zeitschrift Fur Naturforschung. C, Journal of Biosciences|September 1, 1988
Semisynthetic preparation of 1-O-hexadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet activating factor)M E Lekka, D C Tsoukatos, A D Tselepis, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 1, 1995
PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzymeA D Tselepis, C Dentan, S A Karabina, et al.
Journal of Biotechnology|February 7, 2006
Use of ionic liquids as media for the biocatalytic preparation of flavonoid derivatives with antioxidant potencyM H Katsoura, A C Polydera, L Tsironis, et al.
Pageof 6